Breast Cancer Research and Treatment

, Volume 36, Issue 1, pp 11–21 | Cite as

A prospective analysis of immunohistochemically determined hormone receptors and nuclear features as predictors of early recurrence in primary breast cancer

  • Michael Stierer
  • Harald Rosen
  • Renate Weber
  • Hanns Hanak
  • Leo Auerbach
  • Jürgen Spona
  • Heinz Tüchler


The immunohistochemnichally determined receptor status, as well as first-generation risk factors (tumor size, lymph node status, histologic grading including subfactors, tumor histology, and biochemically determined receptor status) were prospectively analyzed in 288 cases of primary breast cancer for their impact on recurrence-free survival (RFS) and overall survival (OS) after a median observation period of 41 months.

Immunohistochemically (ER-ICA) and biochemically determined estrogen receptors (ER-DCC), as well as tumor size, lymph node status, histologic grading, mitotic rate, and nuclear polymorphism, were of prognostic value for recurrence-free survival and/or overall survival.

In multivariate analysis, lymph node status, tumor size, and mitotic rate proved to be independent prognosticators; ER-ICA showed significance in the univariate analysis which dropped, however, when multivariate analysis was applied.

The prognostic power of histologic grading in our series seemed to depend mainly on the subfactors which relate to nuclear features.

Key words

primary breast cancer steroid receptors immunohistochemistry histologic grading prognostic factors 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Early Breast Cancer Trialist's Colloborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339: 1–15, 71-85, 1992Google Scholar
  2. 2.
    Osborne CK, Yochmowitz MG, Knight WA, McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884–2888, 1980Google Scholar
  3. 3.
    Kinne DW, Ashikari R, Butler A, Menendez-Botet C, Rosen PP, Schwartz M: Estrogen receptor protein in breast cancer as a predictor of recurrence. Cancer 47: 2364–2367, 1981Google Scholar
  4. 4.
    Chevallier B, Meintzmann F, Mosseri Vet al.: Prognostic value of estrogen and progesterone receptors in operable breast cancer: results of a univariate and multivariate analysis. Cancer 62: 2517–2524, 1988Google Scholar
  5. 5.
    Hilf R, Feldstein ML, Savlov ED, Gibson SL, Seneca B: The lack of relationship between estrogen receptor status and response to chemotherapy. Cancer 46: 2797–2800, 1980Google Scholar
  6. 6.
    Sears HF, Janus C, Levy W, Hopson R, Creech R: Breast cancer without axillary metastases: Are there high risk biologic subpopulations? Cancer 50: 1820–1827, 1982Google Scholar
  7. 7.
    Shapiro CM, Schiffeling P, Bitran JDet al.: Prognostic value of the estrogen receptor value in pathologic stage I and II adenocarcinoma of the breast. J Surg Oncol 19:119–121, 1982Google Scholar
  8. 8.
    Clark GM, McGuire WL: Progesterone receptors and human breast cancer. Breast Cancer Res Treat 3:157–163, 1983Google Scholar
  9. 9.
    Vollenweider-Zerargui L, Barrelet L, Wong Y, LeMarchand-Beraud T, Gomez F: The predictive value of estrogen and progesterone receptor concentrations on the clinical behaviour of breast cancer in women. Cancer 57: 1171–1180, 1986Google Scholar
  10. 10.
    Alanko A, Heinonen E, Scheinin T, Tolppanen EM, Vihko R: Estrogen and progesterone receptors and disease free interval in primary breast cancer. Br J Cancer 50: 667–672, 1984Google Scholar
  11. 11.
    Thorpe SM, Rose C, Rasmussen BBet al.: Steroid hormone receptors as prognostic indicators in primary breast cancer. Breast Cancer Res Treat (Suppl.) 7: 91–98, 1986Google Scholar
  12. 12.
    Greene GL, Fitch FW, Jensen EV: Monoclonal antibodies to estrophilin: Probes for the study of estrogen receptors. Proc Natl Acad Sci USA 77: 157–161, 1980Google Scholar
  13. 13.
    Perrot-Applanat M, Logeat F, Croyer-Picard MT, Milgrom E: Immunocytochemical study of mammalian progesterone receptor using monoclonal antibodies. Endocrinology 116: 1473–1483, 1985Google Scholar
  14. 14.
    Reiner A, Neumeister B, Spona J, Reiner G, Schemper M, Jakesz R: Immunocytochemical localization of estrogen and progesterone receptors and prognosis in human primary breast cancer. Cancer Res 50: 7057–7061, 1990Google Scholar
  15. 15.
    Pertschuk LP, Feldman JG, Eisenberg KBet al.: Immunocytochemical detection of progesterone receptor in breast cancer with monoclonal antibody. Cancer 62: 342–349, 1988Google Scholar
  16. 16.
    Pertschuk LP, Kim DS, Nayer Ket al.: Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Cancer 66: 1663–1670, 1990Google Scholar
  17. 17.
    Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarthy Jr, KS: Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: Comparison with quantitative biochemical methods. Cancer Res 49: 1052–1056, 1989Google Scholar
  18. 18.
    DeSombre ER, Thorpe SM, Rose Cet al.: Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer. Cancer Res (Suppl) 40: 4256–4264, 1986Google Scholar
  19. 19.
    Gottardi O, Baiocchi C, Ferrari Met al.: Correlation between histochemically assessed hormonal receptor content and clinical course in breast cancer. Oncology 48: 221–225, 1991Google Scholar
  20. 20.
    Bloom HJG, Richardson WW: Histological grading and prognosis in breast carcinoma. Br J Cancer 11: 359–377, 1957Google Scholar
  21. 21.
    Stierer M, Rosen H, Weber R: Nuclear pleomorphism, a strong prognostic factor in axillary node negative small invasive breast cancer. Breast Cancer Res Treat 20: 109–116, 1991Google Scholar
  22. 22.
    Stierer M, Rosen HR, Weber R, Marczell A, Kornek GV, Czerwenka E: Long term analysis of factors influencing the outcome in carcinoma of the breast smaller than one centimeter. Surg Gynecol Obst 175: 151–160, 1992Google Scholar
  23. 23.
    UICC (International Union against Cancer). TNM classification of malignant tumors (3rd ed.). Geneva: UICC, 4754, 1979Google Scholar
  24. 24.
    WHO: The World Health Organization histological typing of breast tumors (2nd ed.). Am J Clin Pathol 78: 806–816, 1982Google Scholar
  25. 25.
    Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long term follow-up. Histopathology 19: 403–410, 1991Google Scholar
  26. 26.
    Bässler R, Böcker W, Hermanek Det al.: Die gegenwärtige Situation des Gradings beim Mammakarzinom. Pathologie 13: 130–134, 1992Google Scholar
  27. 27.
    EORTC Breast Cancer Cooperative Group: Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer Clin Oncol 16: 1513–1515, 1980Google Scholar
  28. 28.
    Remmele W, Stegner HE: Vorschlag zur einheitlichen Definition eines immunreaktiven Score (IRS) für den immunhistochemischen Östrogenrezeptornachweis (ER-ICA) im Mammakarzinomgewebe. Pathologie 8: 138–140, 1987Google Scholar
  29. 29.
    Stierer M, Rosen HR: Influence of early diagnosis on prognosis of recurrent breast cancer. Cancer 64: 1128–1131, 1989Google Scholar
  30. 30.
    Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958Google Scholar
  31. 31.
    Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163–170, 1966Google Scholar
  32. 32.
    Peto R, Pike MD, Armitage Pet al.: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 34: 585–612, 1976Google Scholar
  33. 33.
    Cox DR: Regression models and life tables. JR Stat Soc (B) 34: 187–220, 1972Google Scholar
  34. 34.
    Rosen PP, Groshen S, Saigo PEet al.: A long term follow up study of survival in stage I (TIN0M0) and stage II (TIN0M0) breast carcinoma. J Clin Oncol 7: 355–366, 1989Google Scholar
  35. 35.
    Carter CL, Allen D, Henson DE: Relation of tumor size, lymph node status and survival in 24740 breast cancer cases. Cancer 63: 181–187, 1989Google Scholar
  36. 36.
    Valagussa P, Bonadonna G, Veronesi U: Pattern of relapse and survival following radical mastectomy. Cancer 41: 1170–1178, 1978Google Scholar
  37. 37.
    Rank F, Dombernowsky P, Bang Jesperson NCet al.: Histologic malignancy grading of invasive ductal breast carcinoma. A regression analysis of prognostic factors in low-risk carcinoma from a multicenter trial. Cancer 60: 1299–1305Google Scholar
  38. 38.
    LeDoussal V, Tubiana-Hulin M, Friedman Set al.: Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 64: 1914–1921, 1989Google Scholar
  39. 39.
    Alanko A, Heinonen E, Scheinin T, Tolppanen EM, Vihko R: Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients. Cancer 56: 1696–1700, 1985Google Scholar
  40. 40.
    Rose C, Mouridsen HT, Thorpe SM, Andersen J, Blichert-Toft AL, Andersen KW: Anti-estrogen treatment of postmenopausal breast cancer patients with high risk of recurrence: Seventy-two months of life-table analysis and steroid hormone receptor status. World J Surg 98: 765–774, 1985Google Scholar
  41. 41.
    Fisher ER: Prognostic and therapeutic significance of pathological features of breast cancer. NCI Monogr 1: 29–34, 1986Google Scholar
  42. 42.
    Davies BW, Gelber RD, Goldhirsh Aet al.: Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 58: 2662–2670, 1986Google Scholar
  43. 43.
    Thorpe SM, Rose C, Rasmussen BB, Mouridsen HT, Bayer T, Keiding N (for the Danish Breast Cancer Cooperative Group): Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res 47: 6126–6133, 1987Google Scholar
  44. 44.
    Komitowksy D, Janson C: Quantitative features of chromatin structure in the prognosis of breast cancer. Cancer 65: 2725–2730, 1990Google Scholar
  45. 45.
    Dixon JM, Page DL, Anderson TJet al.: Long term survivors after breast cancer. Br J Surg 72: 445–448, 1985Google Scholar
  46. 46.
    Rapin V, Contesso G, Mouriesse Het al.: Medullary breast carcinoma. A re-evaluation of 95 cases of breast cancer with inflammatory stroma. Cancer 61: 2503–2510, 1988Google Scholar
  47. 47.
    Howell A, Harris M: Infiltrating lobular carcinoma of the breast. Br Med J 291: 1371–1376, 1985Google Scholar
  48. 48.
    Page DL, Anderson TJ: Diagnostic Histopathology of the Breast. Endinburgh, Churchill Livingstone, 1987Google Scholar
  49. 49.
    Stierer M, Rosen H, Weber R, Hanak H, Spona J, Tüchler H: Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer: Correlation of histopathology and prognostic factors. Ann Surg 218: 13–21, 1993Google Scholar
  50. 50.
    Reiner A, Reiner G, Spona J, Schemper M, Holzner H: Histopathologic characterization of human breast cancer in correlation with estrogen receptor status. Cancer 61: 1149–1154, 1988Google Scholar
  51. 51.
    McGuire WL, Dressler LG: Emerging impact of flow cytometry in predicting recurrence and survival in breast cancer patients. J Natl Cancer Inst 75: 405–410, 1985Google Scholar
  52. 52.
    Sigurdsson H, Baldetorp B, Borg Aet al.: Indicators of prognosis in node negative breast cancer. N Engl J Med 322: 1045–1053, 1990Google Scholar
  53. 53.
    Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL: Cathepsin D and prognosis in breast cancer. N Engl J Med 322: 297–302, 1990Google Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • Michael Stierer
    • 1
  • Harald Rosen
    • 2
  • Renate Weber
    • 3
  • Hanns Hanak
    • 3
  • Leo Auerbach
    • 1
  • Jürgen Spona
    • 4
  • Heinz Tüchler
    • 5
  1. 1.Department of SurgeryHanusch Medical CenterViennaAustria
  2. 2.Department of SurgeryDonauspitalViennaAustria
  3. 3.Department of Pathology-HistologyHanusch-KrankenhausViennaAustria
  4. 4.Ludwig Boltzmann-Institut for Experimental Endocrinology, Endocrinol. LaboratoryUniversity of ViennaAustria
  5. 5.Ludwig Boltzmann-Institut for Leukemia Research and HematologyHanusch-KrankenhausViennaAustria

Personalised recommendations